Akero Therapeutics, Inc. $AKRO Stake Trimmed by Aberdeen Group plc

Aberdeen Group plc lowered its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 3.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 391,600 shares of the company’s stock after selling 15,100 shares during the quarter. Aberdeen Group plc owned approximately 0.49% of Akero Therapeutics worth $20,896,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. GF Fund Management CO. LTD. increased its stake in Akero Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company’s stock worth $72,000 after purchasing an additional 321 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Akero Therapeutics by 14.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock worth $114,000 after purchasing an additional 338 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Akero Therapeutics by 30.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock worth $67,000 after purchasing an additional 390 shares in the last quarter. Amalgamated Bank increased its stake in Akero Therapeutics by 19.0% in the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock worth $104,000 after purchasing an additional 410 shares in the last quarter. Finally, Hsbc Holdings PLC increased its stake in Akero Therapeutics by 9.7% in the 1st quarter. Hsbc Holdings PLC now owns 8,647 shares of the company’s stock worth $343,000 after purchasing an additional 761 shares in the last quarter.

Insider Transactions at Akero Therapeutics

In related news, CFO William Richard White sold 659 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $43.02, for a total value of $28,350.18. Following the completion of the sale, the chief financial officer directly owned 57,752 shares in the company, valued at approximately $2,484,491.04. The trade was a 1.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Cheng sold 1,796 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $43.02, for a total value of $77,263.92. Following the completion of the sale, the chief executive officer owned 473,902 shares of the company’s stock, valued at approximately $20,387,264.04. This trade represents a 0.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,253 shares of company stock worth $6,982,414. 7.07% of the stock is currently owned by company insiders.

Akero Therapeutics Stock Down 0.4%

Shares of Akero Therapeutics stock opened at $53.66 on Tuesday. The firm has a market cap of $4.29 billion, a price-to-earnings ratio of -26.83 and a beta of -0.29. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.66 and a quick ratio of 12.66. Akero Therapeutics, Inc. has a 52-week low of $21.34 and a 52-week high of $58.40. The stock has a 50-day simple moving average of $47.25 and a 200-day simple moving average of $46.90.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.11. During the same period last year, the business earned ($0.81) EPS. On average, equities research analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on AKRO shares. Cowen assumed coverage on Akero Therapeutics in a research note on Monday, August 4th. They issued a “buy” rating on the stock. Wolfe Research lowered Akero Therapeutics from an “outperform” rating to a “hold” rating in a research report on Friday. Canaccord Genuity Group lowered Akero Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $73.00 to $54.00 in a research report on Thursday, October 9th. Wall Street Zen lowered Akero Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, TD Cowen assumed coverage on Akero Therapeutics in a research report on Monday, August 4th. They set a “buy” rating and a $76.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $73.38.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.